Supplementary Table 1: Rates, delay, reasons and regimens of IFX optimization.
Whole population BMI<25 25<BMI <30 BMI>30 p Optimization within one year, n (%)
43 (31) 19 (20) 11 (52) 13 (56) 0.0002 Median delay of optimization (IQR),
months 8 (5-10) 10 (6-11) 7 (5-9) 7 (5-10) 0.0311
Median CRP level at optimization (mg/l) (IQR)
11 (5-19) 10 (6-23) 12 (5-21) 9 (7-24) 0.5
CRP > 5 mg/l at IFX optimization, n (%)
30 (70) 12 (63) 8 (73) 10 (77) 0.68
Reasons of optimizations, n (%) 0.95
Primary inefficiency 15 (35) 6 (32) 4 (36) 5 (38)
Loss of response 27 (63) 12(63) 7 (64) 8 (62) Extra-digestive symptoms 1 (2) 1(5) 0 (0) 0 (0) Regimen of optimization, n (%)
- 5mg/kg/7w 5 (12) 3 (16) 1 (9) 1 (8)
- 5mg/kg/6w 10 (23) 4 (21) 2 (18) 4 (31)
- 5mg/kg/4w 14 (33) 6 (32) 4 (36) 4 (31)
- 10mg/kg/8w 14 (33) 6 (32) 4 (36) 4 (31)
Abbreviations: IFX, infliximab; mg, milligrams; CRP, C-reactive protein; BMI, body mass index; HBI, Harvey Bradshaw Index; w, week
Supplementary Table 2: Primary and secondary outcomes within 12 months after IFX introduction in the 3 groups
BMI< 25 25<BMI<30 BMI>30
Median delay of IFX optimization (months) 10 7 7 0.0311
IFX optimization, n (%) (1) 19 (20) 11 (52) 13 (56) 0.0002
Bowel resection surgery and/or perianal 9 (9) 1 (5) 3 (13) 1
surgery n (%) (2)
Introduction CT and/or IS therapy, n (%) (3) 13 (14) 5 (24) 3 (13) IFX treatment withdrawal, n (%) (4) 4 (4) 3 (14) 3 (13) Occurrence of a pejorative event, n (%)
(1/2/3/4)
41 (43) 18 (86) 19 (83) <0.0001
2
